Malaysia’s healthcare sector is gearing up for one of its largest public offerings in nearly a decade, with Sunway Healthcare Holdings Bhd (SHH) set to list on the Main Market on 18 March 2026 at RM1.45 per share, targeting a total raise of RM2.86 billion. As investors prepare to evaluate the IPO, a key question emerges: how does SHH compare to established peers like IHH Healthcare (IHH) and KPJ Healthcare (KPJ), and is the premium valuation justified?
Priced at RM1.45 per share and with an enlarged issued share capital of 1.97 billion shares, SHH would have a market capitalisation of RM16.7 billion, translating to a price-to-earnings ratio (PER) of 64.7x. In comparison, its peer IHH Healthcare trades at a PER of 37.9x, while KPJ Healthcare sits at 37x.
From a growth perspective, SHH stands out. Analysts point to its aggressive expansion plans, which aim to increase licensed bed capacity by 74% to 3,444 by 2032, with potential upside beyond 3,900 beds through additional projects. This expansion is complemented by a strong focus on medical tourism, leveraging the Sunway ecosystem’s hospitality and transport assets to attract international patients. New hospitals are expected to reach EBITDA-positive status within 12–18 months, a significant acceleration compared with the typical three- to five-year ramp-up seen in the sector.
Peers in Perspective: IHH and KPJ
By comparison, IHH with its regional footprint across Malaysia, Singapore, India, and Turkey, emphasises scale and diversification rather than rapid expansion in a single market. It’s hundreds of healthcare facilities provide a stable, geographically diversified revenue base, mitigating the risk of policy or local market shocks. Similarly, KPJ Healthcare, while a respected domestic player, operates primarily in Malaysia with slower expansion plans and moderate growth, resulting in a more conservative earnings trajectory.
Based on its prospectus, SHH recorded the fastest revenue growth among major listed private hospital groups in Southeast Asia during the period, achieving a 31.9% revenue CAGR from FY2022 to FY2024. The group also reported an average revenue per licensed bed of RM1.3 million, which is relatively high compared with its peers. Looking ahead, analysts forecast SHH’s revenue to grow at a three-year CAGR of 14.7% from FY2025 to FY2027, supported by higher occupancy rates and an 11.5% expansion in licensed bed capacity.
Execution Risks Amid Aggressive Growth
However, the company’s aggressive growth strategy carries significant execution risks. Delays in opening new facilities, workforce shortages, or changes to the healthcare payment system—such as the proposed diagnosis-related group (DRG) model—could affect profitability and slow revenue growth. In contrast, IHH’s diversified operations and KPJ’s measured expansion offer more predictable earnings but with lower upside potential.
Ultimately, the SHH IPO represents a classic trade-off between high growth potential and valuation risk. For investors, the key consideration is whether the premium valuation is justified by the potential for rapid expansion, faster-than-average EBITDA ramp-up, and exposure to medical tourism. Compared with IHH and KPJ, SHH offers higher upside but also greater execution risk, meaning success depends heavily on management’s ability to deliver on its ambitious growth plans.
For those seeking long-term growth in Malaysia’s healthcare sector, SHH may be an attractive proposition, provided investors are comfortable with the risks inherent in aggressive expansion. Meanwhile, more cautious investors may prefer IHH or KPJ, whose broader scale or domestic focus offers stability and predictable earnings, albeit with lower potential returns.
Sunway Healthcare’s IPO pricing and business model illustrate the balance between growth opportunity and risk management, highlighting that premium valuations can be justified—but only if expansion is executed successfully. Investors will need to weigh this balance carefully before participating in one of Malaysia’s most anticipated IPOs in recent years.